Ovid Therapeutics (OVID) Expected to Announce Quarterly Earnings on Tuesday

Ovid Therapeutics (NASDAQ:OVID) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $0.0630 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 12:30 PM ET.

Ovid Therapeutics Price Performance

NASDAQ OVID opened at $1.91 on Monday. The stock has a 50-day simple moving average of $1.61 and a 200 day simple moving average of $1.51. Ovid Therapeutics has a twelve month low of $0.24 and a twelve month high of $2.01. The stock has a market capitalization of $136.01 million, a PE ratio of -3.82 and a beta of 0.25. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.24 and a current ratio of 4.24.

Institutional Trading of Ovid Therapeutics

A number of large investors have recently bought and sold shares of OVID. LPL Financial LLC raised its stake in Ovid Therapeutics by 150.0% during the fourth quarter. LPL Financial LLC now owns 30,000 shares of the company’s stock worth $49,000 after acquiring an additional 18,000 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after purchasing an additional 18,841 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Ovid Therapeutics by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 672,004 shares of the company’s stock worth $1,096,000 after purchasing an additional 23,984 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Ovid Therapeutics in the 3rd quarter worth about $33,000. Finally, Invesco Ltd. acquired a new stake in shares of Ovid Therapeutics during the 4th quarter worth about $54,000. 72.24% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OVID. Lifesci Capital began coverage on Ovid Therapeutics in a report on Monday, December 22nd. They set an “outperform” rating and a $4.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Leerink Partners began coverage on shares of Ovid Therapeutics in a research note on Monday, November 17th. They set an “outperform” rating and a $5.00 target price for the company. Finally, Roth Mkm began coverage on shares of Ovid Therapeutics in a report on Thursday, December 11th. They issued a “buy” rating and a $3.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.88.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.